This was the stock's third consecutive day of gains.

TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 ...

Data presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287). Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in the per ...